{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:38:08Z","timestamp":1740137888237,"version":"3.37.3"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T00:00:00Z","timestamp":1643414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T00:00:00Z","timestamp":1643414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LS21H060001"],"award-info":[{"award-number":["LS21H060001"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Alibaba Youth Studio Project","award":["ZJU- 032"],"award-info":[{"award-number":["ZJU- 032"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Sarcomas are highly heterogeneous in molecular, pathologic, and clinical features. However, a classification of sarcomas by integrating different types of pathways remains mostly unexplored.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We performed hierarchical clustering analysis of sarcomas based on the enrichment scores of 14 pathways involved in immune, stromal, DNA damage repair (DDR), and oncogenic signatures in three bulk tumor transcriptome datasets.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Consistently in the three datasets, sarcomas were classified into three subtypes: Immune Class (Imm-C), Stromal Class (Str-C), and DDR Class (DDR-C). Imm-C had the strongest anti-tumor immune signatures and the lowest intratumor heterogeneity (ITH); Str-C showed the strongest stromal signatures, the highest genomic stability and global methylation levels, and the lowest proliferation potential; DDR-C had the highest DDR activity, expression of the cell cycle pathway, tumor purity, stemness scores, proliferation potential, and ITH, the most frequent<jats:italic>TP53<\/jats:italic>mutations, and the worst survival. We further validated the stability and reliability of our classification method by analyzing a single cell RNA-Seq (scRNA-seq) dataset. Based on the expression levels of five genes in the pathways of T cell receptor signaling, cell cycle, mismatch repair, focal adhesion, and calcium signaling, we built a linear risk scoring model (ICMScore) for sarcomas. We demonstrated that ICMScore was an adverse prognostic factor for sarcomas and many other cancers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our classification method provides novel insights into tumor biology and clinical implications for sarcomas.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12967-022-03248-3","type":"journal-article","created":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T10:03:38Z","timestamp":1643450618000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Subtyping of sarcomas based on pathway enrichment scores in bulk and single cell transcriptomes"],"prefix":"10.1186","volume":"20","author":[{"given":"Shengwei","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7199-7093","authenticated-orcid":false,"given":"Xiaosheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,29]]},"reference":[{"issue":"4","key":"3248_CR1","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.cell.2017.10.014","volume":"171","author":"Cancer Genome Atlas Research Network","year":"2017","unstructured":"Cancer Genome Atlas Research Network. Comprehensive and integrated genomic characterization of adult soft tissue sarcomas. Cell. 2017;171(4):950\u201365.","journal-title":"Cell"},{"issue":"3","key":"3248_CR2","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1097\/SLA.0000000000000869","volume":"260","author":"MF Brennan","year":"2014","unstructured":"Brennan MF, et al. Lessons learned from the study of 10,000 patients with soft tissue sarcoma. Ann Surg. 2014;260(3):416\u201321 (discussion 421\u20132).","journal-title":"Ann Surg"},{"issue":"Suppl 1","key":"3248_CR3","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s12881-018-0722-6","volume":"19","author":"J Kim","year":"2018","unstructured":"Kim J, et al. Integrated molecular characterization of adult soft tissue sarcoma for therapeutic targets. BMC Med Genet. 2018;19(Suppl 1):216.","journal-title":"BMC Med Genet"},{"issue":"4","key":"3248_CR4","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/sj.bjc.6600766","volume":"88","author":"YF Lee","year":"2003","unstructured":"Lee YF, et al. Molecular classification of synovial sarcomas, leiomyosarcomas and malignant fibrous histiocytomas by gene expression profiling. Br J Cancer. 2003;88(4):510\u20135.","journal-title":"Br J Cancer"},{"issue":"1","key":"3248_CR5","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41467-020-20603-4","volume":"12","author":"C Koelsche","year":"2021","unstructured":"Koelsche C, et al. Sarcoma classification by DNA methylation profiling. Nat Commun. 2021;12(1):498.","journal-title":"Nat Commun"},{"issue":"1","key":"3248_CR6","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/path.2787","volume":"223","author":"L Gibault","year":"2011","unstructured":"Gibault L, et al. New insights in sarcoma oncogenesis: a comprehensive analysis of a large series of 160 soft tissue sarcomas with complex genomics. J Pathol. 2011;223(1):64\u201371.","journal-title":"J Pathol"},{"key":"3248_CR7","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3389\/fonc.2020.00076","volume":"10","author":"M Saggioro","year":"2020","unstructured":"Saggioro M, et al. Carcinoma and sarcoma microenvironment at a glance: where we are. Front Oncol. 2020;10:76.","journal-title":"Front Oncol"},{"issue":"8","key":"3248_CR8","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/nrc3087","volume":"11","author":"BS Taylor","year":"2011","unstructured":"Taylor BS, et al. Advances in sarcoma genomics and new therapeutic targets. Nat Rev Cancer. 2011;11(8):541\u201357.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"3248_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0009747","volume":"5","author":"PA Konstantinopoulos","year":"2010","unstructured":"Konstantinopoulos PA, et al. Analysis of multiple sarcoma expression datasets: implications for classification, oncogenic pathway activation and chemotherapy resistance. PLoS ONE. 2010;5(4): e9747.","journal-title":"PLoS ONE"},{"issue":"1","key":"3248_CR10","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1186\/s12974-020-02030-w","volume":"17","author":"Q Feng","year":"2020","unstructured":"Feng Q, et al. Immunological classification of gliomas based on immunogenomic profiling. J Neuroinflammation. 2020;17(1):360.","journal-title":"J Neuroinflammation"},{"key":"3248_CR11","doi-asserted-by":"publisher","first-page":"4472","DOI":"10.1016\/j.csbj.2021.08.005","volume":"19","author":"Q Liu","year":"2021","unstructured":"Liu Q, et al. Identification of subtypes correlated with tumor immunity and immunotherapy in cutaneous melanoma. Comput Struct Biotechnol J. 2021;19:4472\u201385.","journal-title":"Comput Struct Biotechnol J"},{"key":"3248_CR12","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.omto.2020.03.021","volume":"17","author":"F Xu","year":"2020","unstructured":"Xu F, et al. Analysis of lung adenocarcinoma subtypes based on immune signatures identifies clinical implications for cancer therapy. Mol Ther Oncolytics. 2020;17:241\u20139.","journal-title":"Mol Ther Oncolytics"},{"key":"3248_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118368","volume":"261","author":"M Li","year":"2020","unstructured":"Li M, et al. An immune landscape based prognostic signature predicts the immune status and immunotherapeutic responses of patients with colorectal cancer. Life Sci. 2020;261: 118368.","journal-title":"Life Sci"},{"key":"3248_CR14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S Hanzelmann","year":"2013","unstructured":"Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 2013;14:7.","journal-title":"BMC Bioinform"},{"issue":"43","key":"3248_CR15","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3248_CR16","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara K, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.","journal-title":"Nat Commun"},{"issue":"1","key":"3248_CR17","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.celrep.2018.03.076","volume":"23","author":"TA Knijnenburg","year":"2018","unstructured":"Knijnenburg TA, et al. Genomic and molecular landscape of DNA damage repair deficiency across The Cancer Genome Atlas. Cell Rep. 2018;23(1):239-254 e6.","journal-title":"Cell Rep"},{"issue":"1","key":"3248_CR18","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/s42003-020-01230-7","volume":"3","author":"M Li","year":"2020","unstructured":"Li M, et al. An algorithm to quantify intratumor heterogeneity based on alterations of gene expression profiles. Commun Biol. 2020;3(1):505.","journal-title":"Commun Biol"},{"issue":"4","key":"3248_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2011-12-4-r41","volume":"12","author":"CH Mermel","year":"2011","unstructured":"Mermel CH, et al. GISTIC20 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011;12(4): R41.","journal-title":"Genome Biol"},{"issue":"1","key":"3248_CR20","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/nprot.2014.006","volume":"9","author":"S Picelli","year":"2014","unstructured":"Picelli S, et al. Full-length RNA-seq from single cells using Smart-seq2. Nat Protoc. 2014;9(1):171\u201381.","journal-title":"Nat Protoc"},{"issue":"11","key":"3248_CR21","first-page":"2579","volume":"9","author":"L Van der Maaten","year":"2008","unstructured":"Van der Maaten L, Hinton G. Visualizing data using t-SNE. J Mach Learn Res. 2008;9(11):2579\u2013605.","journal-title":"J Mach Learn Res"},{"key":"3248_CR22","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B. 1995;57:289\u2013300.","journal-title":"J R Stat Soc B"},{"issue":"7","key":"3248_CR23","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1158\/0008-5472.CAN-10-3588","volume":"71","author":"RM Gobble","year":"2011","unstructured":"Gobble RM, et al. Expression profiling of liposarcoma yields a multigene predictor of patient outcome and identifies genes that contribute to liposarcomagenesis. Cancer Res. 2011;71(7):2697\u2013705.","journal-title":"Cancer Res"},{"key":"3248_CR24","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ejca.2015.12.027","volume":"57","author":"T Lesluyes","year":"2016","unstructured":"Lesluyes T, et al. RNA sequencing validation of the Complexity INdex in SARComas prognostic signature. Eur J Cancer. 2016;57:104\u201311.","journal-title":"Eur J Cancer"},{"key":"3248_CR25","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/ncomms1734","volume":"3","author":"A Akhmetshina","year":"2012","unstructured":"Akhmetshina A, et al. Activation of canonical Wnt signalling is required for TGF-beta-mediated fibrosis. Nat Commun. 2012;3:735.","journal-title":"Nat Commun"},{"issue":"2","key":"3248_CR26","volume":"10","author":"S Jiang","year":"2020","unstructured":"Jiang S, et al. Cell cycle activity correlates with increased anti-tumor immunity in diverse cancers. Clin Transl Med. 2020;10(2): e98.","journal-title":"Clin Transl Med"},{"issue":"4","key":"3248_CR27","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/path.5155","volume":"246","author":"AM McCorry","year":"2018","unstructured":"McCorry AM, et al. Epithelial-to-mesenchymal transition signature assessment in colorectal cancer quantifies tumour stromal content rather than true transition. J Pathol. 2018;246(4):422\u20136.","journal-title":"J Pathol"},{"key":"3248_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2018.27","author":"JC Del Paggio","year":"2018","unstructured":"Del Paggio JC. Immunotherapy: cancer immunotherapy and the value of cure. Nat Rev Clin Oncol. 2018. https:\/\/doi.org\/10.1038\/nrclinonc.2018.27.","journal-title":"Nat Rev Clin Oncol"},{"issue":"18","key":"3248_CR29","doi-asserted-by":"publisher","first-page":"9020","DOI":"10.1073\/pnas.1818210116","volume":"116","author":"A Miranda","year":"2019","unstructured":"Miranda A, et al. Cancer stemness, intratumoral heterogeneity, and immune response across cancers. Proc Natl Acad Sci USA. 2019;116(18):9020\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3248_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.dnarep.2020.102785","author":"L Li","year":"2020","unstructured":"Li L, Li MY, Wang XS. Cancer type-dependent correlations between TP53 mutations and antitumor immunity. DNA Repair. 2020. https:\/\/doi.org\/10.1016\/j.dnarep.2020.102785.","journal-title":"DNA Repair"},{"issue":"1","key":"3248_CR31","doi-asserted-by":"publisher","first-page":"624","DOI":"10.18632\/oncotarget.13483","volume":"8","author":"X Wang","year":"2017","unstructured":"Wang X, Sun Q. TP53 mutations, expression and interaction networks in human cancers. Oncotarget. 2017;8(1):624\u201343.","journal-title":"Oncotarget"},{"key":"3248_CR32","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a026096","author":"CM Eischen","year":"2016","unstructured":"Eischen CM. Genome stability requires p53. Cold Spring Harb Perspect Med. 2016. https:\/\/doi.org\/10.1101\/cshperspect.a026096.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"1","key":"3248_CR33","doi-asserted-by":"publisher","first-page":"4278","DOI":"10.1038\/s41467-019-12159-9","volume":"10","author":"H Jung","year":"2019","unstructured":"Jung H, et al. DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load. Nat Commun. 2019;10(1):4278.","journal-title":"Nat Commun"},{"issue":"6","key":"3248_CR34","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nri2765","volume":"10","author":"A Mocsai","year":"2010","unstructured":"Mocsai A, Ruland J, Tybulewicz VL. The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol. 2010;10(6):387\u2013402.","journal-title":"Nat Rev Immunol"},{"issue":"20","key":"3248_CR35","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1016\/j.cub.2005.09.050","volume":"15","author":"HC Welch","year":"2005","unstructured":"Welch HC, et al. P-Rex1 regulates neutrophil function. Curr Biol. 2005;15(20):1867\u201373.","journal-title":"Curr Biol"},{"issue":"48","key":"3248_CR36","doi-asserted-by":"publisher","first-page":"7990","DOI":"10.1038\/sj.onc.1208074","volume":"23","author":"EH Palacios","year":"2004","unstructured":"Palacios EH, Weiss A. Function of the Src-family kinases, Lck and Fyn T-cell development and activation. Oncogene. 2004;23(48):7990\u20138000.","journal-title":"Oncogene"},{"issue":"1","key":"3248_CR37","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/nri2470","volume":"9","author":"M Perretti","year":"2009","unstructured":"Perretti M, D\u2019Acquisto F. Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. Nat Rev Immunol. 2009;9(1):62\u201370.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"3248_CR38","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1083\/jcb.130.2.451","volume":"130","author":"L Piali","year":"1995","unstructured":"Piali L, et al. CD31\/PECAM-1 is a ligand for alpha v beta 3 integrin involved in adhesion of leukocytes to endothelium. J Cell Biol. 1995;130(2):451\u201360.","journal-title":"J Cell Biol"},{"issue":"4","key":"3248_CR39","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.immuni.2012.08.015","volume":"37","author":"J Mjosberg","year":"2012","unstructured":"Mjosberg J, et al. The transcription factor GATA3 is essential for the function of human type 2 innate lymphoid cells. Immunity. 2012;37(4):649\u201359.","journal-title":"Immunity"},{"issue":"4","key":"3248_CR40","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1089\/jir.2015.0054","volume":"36","author":"A Rani","year":"2016","unstructured":"Rani A, Murphy JJ. STAT5 in cancer and immunity. J Interferon Cytokine Res. 2016;36(4):226\u201337.","journal-title":"J Interferon Cytokine Res"},{"key":"3248_CR41","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf8399","author":"T Davoli","year":"2017","unstructured":"Davoli T, et al. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science. 2017. https:\/\/doi.org\/10.1126\/science.aaf8399.","journal-title":"Science"},{"issue":"4","key":"3248_CR42","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","volume":"48","author":"V Thorsson","year":"2018","unstructured":"Thorsson V, et al. The immune landscape of cancer. Immunity. 2018;48(4):812\u201383014.","journal-title":"Immunity"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-022-03248-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-022-03248-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-022-03248-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T15:46:00Z","timestamp":1726587960000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-022-03248-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,29]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["3248"],"URL":"https:\/\/doi.org\/10.1186\/s12967-022-03248-3","relation":{},"ISSN":["1479-5876"],"issn-type":[{"type":"electronic","value":"1479-5876"}],"subject":[],"published":{"date-parts":[[2022,1,29]]},"assertion":[{"value":"27 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval and consent to participate were waived since we used only publicly available data and materials in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors read and approved the publication of the final manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"48"}}